Factor XIII Concentrate

In February 2011, the plasma-derived CLS Behring factor XIII concentrate Corifact™received US Food and Drug Administration (FDA) clearance to provide bleeding prophylaxis for patients with rare congenital factor XIII (fibrin stabilizing factor) deficiency. In January, 2013, the FDA extended Corifact’s indication to include management of perioperative bleeding in factor XIII-deficient patients. The Corifact package insert is attached here:

Corifact Prescribing Information